NCT07895693Recrutement en cours
Comprehensive Palliative Care After Stem Cell Transplantation: a Feasability Study
Résumé
People who receive an allogeneic stem cell transplant often face important physical and emotional challenges during their recovery. Even after leaving the hospital, they may experience symptoms such as fatigue, pain, anxiety, uncertainty, or difficulties returning to their usual daily activities. Family caregivers may also experience a considerable burden during this period. Palliative care is specialized supportive care aimed at improving quality of life for people facing serious illness. It focuses on helping patients and families manage symptoms, cope with emotional and practical challenges, and receive care that is aligned with their needs and priorities. While palliative care is increasingly integrated into cancer care, it is not routinely offered to all patients recovering from stem cell transplantation. The COMPAS study aims to determine whether it is feasible and acceptable to systematically offer palliative care consultations to patients after allogeneic stem cell transplantation. Participants will receive supportive consultations with a palliative care physician in addition to their usual transplant follow-up care. The study will evaluate whether patients are willing to participate, whether the consultations can be delivered as planned, and how patients and caregivers perceive this approach. Participants and caregivers will also be invited to complete questionnaires and some may take part in interviews about their experience. The results of this study will help determine whether a larger future study should be conducted and may contribute to improving supportive care for people recovering from stem cell transplantation.
Critères d'inclusion
• Adults aged 18 years or older. • Undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). • Meet at least one of the following vulnerability criteria: Heavy symptom burden, defined as a score of 3 or higher for at least one symptom on the Edmonton Symptom Assessment System (ESAS); Age 65 years or older; Poor prognosis, defined as a Disease Risk Index (DRI) category of intermediate, high, or very high. • Able to provide written informed consent. • Able to communicate in French and complete study assessments.
Critères d'exclusion
• Severe cognitive impairment preventing completion of study questionnaires. • Inability to provide informed consent. • Inability to communicate in French.
Contacts
Les coordonnées de l'équipe de l'essai s'affichent sur demande.
Voir la fiche officielle de l'essai- Statut
- Recrutement en cours
- Phase
- Sans phase (N/A)
- Type d'étude
- Interventionnelle
- Pays
- Suisse
- Promoteur
- Lisa Hentsch(Autre)
- N° de protocole
- COMPAS
- Pathologies
- Hematopoietic Stem Cell Transplantation (HSCT)
- Interventions
- Comportemental
Traitements évalués
- Early Integrated Palliative Care
Lieux · 1
- Geneva, SuisseGeneva University HospitalsRecrute dans ce centre
Au total, dans le monde, le seul centre listé au registre recrute.
Statut par centre selon le registre ClinicalTrials.gov (dernière mise à jour publiée : 26 octobre 2026).
Ce statut peut avoir changé et ne dit rien de votre éligibilité : avant toute démarche, vérifiez avec votre oncologue ou le centre.
Voir aussi
Autres versions
Ces résultats sont indicatifs et ne remplacent pas un avis médical — à discuter avec votre médecin.